A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis.

ABSTRACT:

Background

Psoriasis is a chronic immune-mediated inflammatory systemic disease with skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques resulting from hyperproliferation of keratinocytes. Certolizumab pegol [CZP], a PEGylated antigen binding fragment of a humanized monoclonal antibody against TNF-alpha, is approved for the treatment of moderate-to-severe plaque psoriasis. Patients with psoriasis present clinical and molecular variability, affecting response to treatment. Herein, we utilized an in silico approach to model the effects of CZP in a virtual population (vPop) with moderate-to-severe psoriasis. Our proof-of-concept study aims to assess the performance of our model in generating a vPop and defining CZP response variability based o

SUBMITTER: Coto-Segura P 

PROVIDER: S-EPMC10552644 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature